ISSN: 1300-7777 E-ISSN: 1308-5263
Consecutive IL-2 and IFN-a2a Maintenance in a Patient with Acute Non-lymphoblastic Leukemia and Renal Cell Cancer [Turk J Hematol]
Turk J Hematol. 2001; 18(3): 207-210

Consecutive IL-2 and IFN-a2a Maintenance in a Patient with Acute Non-lymphoblastic Leukemia and Renal Cell Cancer

Akın Uysal1, Muhit Özcan1, Celalettin Üstün1, Semin Fenkçi1
Ankara University, Medical Faculty, İbn-i Sina Hospital, Department Of Haematology, Ankara, Turkey

Over the last few years, the use of ınterleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells have been found to be effective in the treatment of some solid tumours and acute myeloid leukemia. Our patient was initially diagnosed as having bilateral synchronous renal cell cancer (RCC) and underwent nephrectomy. Approximately two years after the operation he developed leukopenia without any sign of residual renal cell cancer. Bone marrow examination revealed acute myeloblastic leukemia (AML). IL-2 following IFN-a2a was used as a maintenance therapy after a standard remission induction and a consolidation therapy. Our patient has been still disease free for 58 months after the diagnosis of AML and 71 months after the diagnosis renal cell cancer. Review of the literature showed that this is the first case who has both RCC and AML and was treated successfully with IL-2 and IFN-a2a.

Keywords: IL-2, IFN-a2a, Renal cell cancer, ANLL.


Akın Uysal, Muhit Özcan, Celalettin Üstün, Semin Fenkçi. Consecutive IL-2 and IFN-a2a Maintenance in a Patient with Acute Non-lymphoblastic Leukemia and Renal Cell Cancer. Turk J Hematol. 2001; 18(3): 207-210, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686